Cargando…

Alzheimer's Disease: Another Target for Heparin Therapy

Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-β(A-β), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergamaschini, Luigi, Rossi, Emanuela, Vergani, Carlo, De Simoni, Maria Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823143/ https://www.ncbi.nlm.nih.gov/pubmed/19734963 http://dx.doi.org/10.1100/tsw.2009.100

Ejemplares similares

Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
por: Honore, Patrick M., et al.
Publicado: (2016)

Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids
por: Petrillo, Maria Grazia, et al.
Publicado: (2014)

Acute Stent Thrombosis and Heparin Induced Thrombocytopenia: Another Manifestation of Kounis Syndrome?
por: Kounis, Nicholas G, et al.
Publicado: (2013)

Emerging actionable targets to treat therapy-resistant colorectal cancers
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Alzheimer's disease biomarkers: another tool for FAA pilot screening?
por: Lawrence, Matthew W, et al.
Publicado: (2019)

Preclinical Alzheimer’s dementia: a useful concept or another dead end?
por: Mark, Ruth E., et al.
Publicado: (2022)

Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease
por: Hayman, Erik G., et al.
Publicado: (2017)

Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases
por: Kondashevskaya, M. V.
Publicado: (2022)

Heparin and Derivatives for Advanced Cell Therapies
por: Laner-Plamberger, Sandra, et al.
Publicado: (2021)

Gut microbiome-targeted therapies for Alzheimer’s disease
por: Zhang, Tao, et al.
Publicado: (2023)

Iron and Targeted Iron Therapy in Alzheimer’s Disease
por: Wang, Jian, et al.
Publicado: (2023)

Dysfunctional macrophages in Alzheimer Disease: another piece of the “macroph-aging” puzzle?
por: Costarelli, Laura, et al.
Publicado: (2017)

Bilateral iliopsoas intramuscular bleeding following anticoagulant therapy with heparin: a case report
por: Murena, Luigi, et al.
Publicado: (2009)

Sodium Intake and Disease: Another Relationship to Consider
por: Baumer-Harrison, Caitlin, et al.
Publicado: (2023)

Comprehensive Landscape of Heparin Therapy for COVID-19
por: Shi, Chen, et al.
Publicado: (2021)

Heparin in Penicillin Therapy
por: Martin, Peter
Publicado: (1945)

Another coronavirus, another epidemic, another warning
por: Poland, Gregory A.
Publicado: (2020)

Targeting HDACs: A Promising Therapy for Alzheimer's Disease
por: Xu, Ke, et al.
Publicado: (2011)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Doxofylline is not just another theophylline!
por: Matera, Maria Gabriella, et al.
Publicado: (2017)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

Targeting neuroinflammation in Alzheimer’s disease
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2016)

Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
por: Stopschinski, Barbara E., et al.
Publicado: (2023)

Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?
por: Mossello, Enrico, et al.
Publicado: (2010)

Neisseria Heparin Binding Antigen is targeted by the human alternative pathway C3-convertase
por: Di Fede, Martina, et al.
Publicado: (2018)

C1-inhibitor attenuates neurobehavioral deficits following controlled cortical impact brain injury in mice
por: Longhi, L, et al.
Publicado: (2007)

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study
por: Colombo, Delia, et al.
Publicado: (2018)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy
por: Wang, Tao, et al.
Publicado: (2023)

Identifying Novel Actionable Targets in Colon Cancer
por: Cerrito, Maria Grazia, et al.
Publicado: (2021)

Mitochondrial Dysfunction: Different Routes to Alzheimer's Disease Therapy
por: Picone, Pasquale, et al.
Publicado: (2014)

Liraglutide: another reason to target prediabetes?
por: Murphy, Conor F., et al.
Publicado: (2017)

Another Decade, Another Coronavirus
por: Perlman, Stanley
Publicado: (2020)

Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases
por: Zhang, Wenjuan, et al.
Publicado: (2019)

Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends
por: Ghiselli, Giancarlo
Publicado: (2019)

Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy
por: Yin, Tong, et al.
Publicado: (2023)

Another Look at Atlantis
por: Kleeman, Stuart
Publicado: (1969)

Pharmacotherapeutic targets in Alzheimer's disease
por: Biran, Yif'at, et al.
Publicado: (2009)

Yawn contagion in bonobos: Another group, another story
por: Norscia, Ivan, et al.
Publicado: (2022)

General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market
por: Al-Hakim, Ali
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2avbkugc42l76hfvllhua51ook